Total Funding
66
59
Total FundingSeries A raised
Growth Score 66 in past quarter
-7 pts
Heat Score 59 in past quarter
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
31379
A diagnostics platform that makes liquid biopsies a reality in cancer care
- Tommi Lehtonen: Co-Founder, CEOPast Role: Quest Diagnostics, VP & GM of Specialty Genetics
Damien Lapray: Co-Founder, Chief Commercial OfficerPast Role: SOPHiA GENETICS, Chief Commercial Officer
About the Company
With the use of Hedera Dx's liquid biopsy solution, hospital labs will be able to conduct clinically useful liquid biopsies on their own. This will greatly simplify tumor profiling. It is difficult to accomplish IVD compliance, privacy infrastructure, and validation, and even if these challenges are overcome, the current software workflows are
inefficient to use and lack key capabilities.
Hedera Dx was established on July 1, 2021 in Epalinges, Vaud.